Gosset GSK VIDRU

Historical infectious disease vaccine benchmarks

Established diseases had higher progression rates

The gap between new and established disease areas widened in later phases.

Recorded Pharmapremia outcomes Published BIO / Pharmapremia
Published BIO

Phase 1 → 2

New diseases 55% Established diseases 57% 49%

Phase 2 → 3

New diseases 31% Established diseases 48% 35%

Phase 3 → filing

New diseases 43% Established diseases 82% 67%

Rates use programs with recorded outcomes for each phase, counted by indication. HIV treatment is excluded. BIO’s published rates cover a separate 2013–2022 cohort.